ALX Oncology Holdings Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-101.7M | $-134.9M | $-160.8M | $-123.5M | $-83.5M | $-45.7M | $-19.2M | $-13.7M |
| Depreciation & Amortization | $706.0K | $872.0K | $836.0K | $342.0K | $51.0K | $202.0K | $429.0K | $431.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $12.6M | $27.1M | $26.3M | $23.8M | $13.9M | $5.4M | $297.0K | $269.0K |
| Net Cash from Operating Activities | $-84.1M | $-121.9M | $-130.4M | $-89.2M | $-68.1M | $-38.3M | $-14.2M | $-13.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $212.0K | $447.0K | $1.3M | $1.4M | $666.0K | $31.0K | $353.0K | $653.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $82.6M | $86.3M | $44.7M | $-235.4M | $-4.9M | $610.0K | $-353.0K | $-653.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | $6.0K |
| Net Cash from Financing Activities | $362.0K | $30.8M | $59.3M | $9.9M | $2.5M | $462.9M | $15.4M | $1.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-84.4M | $-122.4M | $-131.6M | $-90.7M | $-68.8M | $-38.3M | $-14.6M | $-13.8M |